SENTI BIOSCIENCES HOLDINGS, INC.
Profile
Company Names
SENTI BIOSCIENCES HOLDINGS, INC.
SENTI BIOSCIENCES, INC.
Addresses
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA 94080
Phone Numbers
650-239-2030
(650) 382-3281
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
2021
State Incorporated:
DELAWARE
Total Amount Raised:
$47,604,250.00
Number of Funding Rounds:
2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2026-05-20
$10,000,000.00
$40,000,000.00
$30,000,000.00
Debt
1
2024-12-09
$37,604,250.00
$120,594,900.00
$82,990,650.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
BRYAN
BAUM
DIRECTOR
OPERAM INC.
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES CB
| K5 SPACE EXPLORATION, LP - SERIES 1
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES CB2
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES FP
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES LB
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES HORIZONS BORING
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES RELATIVITY SPACE 2
| K5 GLOBAL TECHNOLOGY FUND, LP - RELATIVITY SPACE RF 3
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES RELATIVITY SPACE 5
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES 002
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES 001
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES 003
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES 006
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES 004
| MBK CAPITAL LP - SERIES 101
| K5 GLOBAL GROWTH I, LP
| MBK CAPITAL, LP - SERIES 104
| MBK CAPITAL LP - SERIES 105
| MBK CAPITAL, LP - SERIES 106
| K5 SPACE EXPLORATION LP - SERIES 2
| MBK CAPITAL, LP - SERIES 107
| MOUNT OLYMPUS CAPITAL, LP
| K5 GLOBAL GROWTH FUND II, LP
| K5X FUND I, LP
| K5 GLOBAL TECHNOLOGY FUND, LP - SERIES 007
| K5 TOKYO BLACK FUND I, LP
| CORAM AI INC.
| K5 TECH FUND I, LP - SERIES 104
| SPRINTER SPIRITS, INC.
| K5 TECH FUND I, LP - SERIES 107
| K5 TECH FUND I, LP - SERIES 106
| K5 TECH FUND I, LP - SERIES 110
| KHLOUD, INC.
| K5 TECH FUND I, LP - SERIES 111
| K5 TECH FUND I, LP - SERIES 114
| K5 TECH FUND I, LP - SERIES 112
| AJRX, LLC
| K5 TECH FUND I, LP - SERIES 108
| SPIR LLC
| K5 TECH FUND I, LP - SERIES 116
| K5 TECH FUND I, LP - SERIES 109
| K5 HS HOLDCO, LLC
| AJRX III, LLC
| K5 TECH FUND II, LP - SERIES 202
| K5 TECH FUND II, LP - SERIES 201
| K5 TECH FUND II, LP - SERIES 205
| K5 TECH FUND II, LP - SERIES 204
| K5 TECH FUND I, LP - VENTURES III-B
| K5 TECH FUND II, LP - SERIES 203
| SENTI BIOSCIENCES HOLDINGS, INC.
| SENTI HOLDINGS, INC.
| SENTI BIOSCIENCES, INC.
| K5 TECH FUND II, LP - SERIES 206
| K + SODA, INC.
JAMES
COLLINS
DIRECTOR
SAF-T-PAY, INC
| MOTHER AFRICKA PARTNERS LLC
| PHOTO HOLDINGS, INC.
| BCB BANCORP INC
| FULCRUM THERAPEUTICS, INC.
| SHERLOCK BIOSCIENCES, INC.
| AWAKN LIFE SCIENCES INC.
| BAREFOOT BITCOIN FUND I LLC
| GOLOCKER ENTERPRISES, INC.
| AWAKN LIFE SCIENCES CORP.
| BEFORE SELF CARE CO INC.
| SENTI BIOSCIENCES, INC.
JAMES
J.
COLLINS
DIRECTOR
BRENDA
COOPERSTONE
DIRECTOR
JAY
CROSS
EXECUTIVE OFFICER
FENG
HSIUNG
DIRECTOR
JORVIK MULTI-STRATEGY DOMESTIC FUND, L.P.
| YORK SELECT LP
| YORK TOTAL RETURN LP
| YORK EUROPEAN FOCUS FUND LP
| YORK CREDIT OPPORTUNITIES FUND LP
| YORK ASIAN OPPORTUNITIES FUND LP
| YORK EUROPEAN OPPORTUNITIES FUND LP
| YORK INSTITUTIONAL PARTNERS LP
| YTR INVESTORS, L.P.
| YORK CAPITAL MANAGEMENT L P
| ACION ONSHORE FUND
| SENTI BIOSCIENCES HOLDINGS, INC.
| SENTI HOLDINGS, INC.
| SENTI BIOSCIENCES, INC.
TIMOTHY
LU
EXECUTIVE OFFICER, DIRECTOR
EDWARD
MATHERS
DIRECTOR
RA PHARMACEUTICALS, INC.
| RHYTHM PHARMACEUTICALS, INC.
| SATORI PHARMACEUTICALS INC
| MIRNA THERAPEUTICS, INC.
| RHYTHM HOLDING COMPANY, LLC
| LUMENA PHARMACEUTICALS, INC.
| LUMOS PHARMA, INC.
| AMPLYX PHARMACEUTICALS, INC.
| LIQUIDIA TECHNOLOGIES INC
| INOZYME PHARMA, INC.
| SYNLOGIC, INC.
| AFFINIA THERAPEUTICS INC.
| CODE BIOTHERAPEUTICS, INC.
| TREVI THERAPEUTICS, INC.
| SORRISO PHARMACEUTICALS, INC.
| MBX BIOSCIENCES, INC.
| CARDURION PHARMACEUTICALS, INC.
| BRENIG THERAPEUTICS, INC.
| SENTI BIOSCIENCES, INC.
| SENTI BIOSCIENCES HOLDINGS, INC.
| SENTI HOLDINGS, INC.
| SENTI BIOSCIENCES, INC.
KANYA
RAJANGAM
EXECUTIVE OFFICER
FRANCES
D.
SCHULZ
DIRECTOR
DONALD
TANG
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Debt
2026-05-20
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Debt
2026-05-20
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Debt
2026-05-20
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2024-12-09
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
